全文获取类型
| 收费全文 | 527篇 |
| 免费 | 54篇 |
| 国内免费 | 27篇 |
专业分类
| 儿科学 | 2篇 |
| 妇产科学 | 7篇 |
| 基础医学 | 8篇 |
| 临床医学 | 18篇 |
| 内科学 | 51篇 |
| 神经病学 | 1篇 |
| 特种医学 | 3篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 20篇 |
| 综合类 | 47篇 |
| 预防医学 | 11篇 |
| 药学 | 129篇 |
| 1篇 | |
| 中国医学 | 5篇 |
| 肿瘤学 | 304篇 |
出版年
| 2023年 | 5篇 |
| 2022年 | 1篇 |
| 2021年 | 9篇 |
| 2020年 | 15篇 |
| 2019年 | 8篇 |
| 2018年 | 14篇 |
| 2017年 | 21篇 |
| 2016年 | 20篇 |
| 2015年 | 24篇 |
| 2014年 | 40篇 |
| 2013年 | 38篇 |
| 2012年 | 48篇 |
| 2011年 | 54篇 |
| 2010年 | 38篇 |
| 2009年 | 65篇 |
| 2008年 | 62篇 |
| 2007年 | 37篇 |
| 2006年 | 27篇 |
| 2005年 | 22篇 |
| 2004年 | 14篇 |
| 2003年 | 12篇 |
| 2002年 | 4篇 |
| 2001年 | 3篇 |
| 2000年 | 5篇 |
| 1999年 | 5篇 |
| 1998年 | 9篇 |
| 1997年 | 2篇 |
| 1996年 | 2篇 |
| 1995年 | 4篇 |
排序方式： 共有608条查询结果，搜索用时 46 毫秒
41.
Okuma Y Hosomi Y Takagi Y Iguchi M Okamura T Shibuya M 《Lung cancer (Amsterdam, Netherlands)》2011,74(3):492-496
Background
Thymic carcinoma is a rare, malignant mediastinal tumor that is definitively distinguished from thymoma by its wide extensiveness and poor prognosis. At present, cisplatin-based triplet or quartet chemotherapy with the second generation antitumor agents, referred to as Einhorn's protocol for germ cell tumors, is used as first-line chemotherapy for advanced thymic carcinoma, though an optimal chemotherapeutic regimen has not yet been established. In this retrospective study, the effectiveness and toxicity of cisplatin and irinotecan combination chemotherapy were evaluated over a nine-year period.Patients and methods
Patients with advanced thymic carcinoma who were treated with cisplatin and irinotecan combination chemotherapy between January 1, 2002 and December 31, 2010, were retrospectively identified from our database and medical records. The endpoints in this study were disease control, response rate, progression-free survival (PFS), and overall survival (OS). Significant hematological and non-hematological toxicities were also assessed.Results
Among identified nine patients, disease control was achieved in 8 patients (88.9%), and a clinical response was achieved in 5 (55.6%). The median PFS was 7.9 months, and the median OS was 33.8 months. One- and two-year OS were 77.7% and 55.6%, respectively. Grade 3/4 hematological toxicities were observed in 2 patients (22.2%), and Grade 3/4 non-hematological toxicities were seen in 2 patients (22.2%). No febrile neutropenia or toxic death was recorded.Conclusion
Cisplatin and irinotecan combination chemotherapy appears to be acceptable for advanced thymic carcinoma as first-line chemotherapy with respect to efficacy, toxicity, and usage in the clinical setting. 相似文献42.
43.
目的 探讨Carfilzomib（CFZ）联合伊立替康（CPT-11）对胃癌SGC-7901细胞增殖、凋亡及核因子（NF）-κB水平的影响。方法 采用噻唑蓝比色法检测不同浓度CFZ（0、0.1、1、10、50、100nmol／L）或CPT-11（0、2.5、5、10、50、100μmol／L）及100nmol／L CFZ联合100μmol／L CPT-11处理SGC-7901细胞24、48、72、96h的增殖抑制率,采用流式细胞仪Annexin V／PI双染流式细胞术检测CFZ联合CPT-11处理48h的凋亡率和细胞周期,流式细胞术检测细胞内活化caspase 3的表达,采用Western blotting检测CFZ联合CPT-11处理48h的NF-κB、IκB-α水平及PI3K／Akt信号通路的活化情况。结果 CFZ联合CPT-11或两者单用可呈时间和剂量依赖的方式升高SGC-7901细胞增殖抑制率,且CFZ联合CPT-11的增殖抑制率高于CFZ或CPT-11单用,差异有统计学意义（P＜0.05）;与CFZ或CPT-11单用相比,CFZ联合CPT-11处理48h的凋亡率、caspase-3活化率、S期细胞比例及IκB-α水平均升高, G2／M期细胞比例、NF-κB p65及p-Akt 水平均降低,差异均有统计学意义（P＜0.05）。结论 CFZ和CPT-11对胃癌SGC-7901细胞均有细胞毒性,如抑制增殖、诱导凋亡、下调NF-κB及抑制PI3K／Akt信号通路活化,CFZ联合CPT-11对胃癌细胞具有协同增效的作用。 相似文献
44.
Kazushige Kawai Eiji Sunami Keisuke Hata Toshiaki Tanaka Takeshi Nishikawa Kensuke Otani Kazuhito Sasaki Hiroaki Nozawa 《Clinical colorectal cancer》2018,17(3):240-246
Introduction
Chemoradiotherapy (CRT) is the standard treatment for locally advanced rectal cancer; however, the optimal chemotherapy sequence to administer simultaneously with radiotherapy remains unclear. We conducted a phase I/II study to test a new regimen, TEGAFIRI (combination tegafur, uracil [UFT], leucovorin [LV], irinotecan), for patients with locally advanced rectal cancer.Patients and Methods
A total of 22 patients with locally advanced lower rectal adenocarcinoma were enrolled in the present study. The radiation dose was 50.4 Gy in 28 fractions. UFT (300 mg/m2/d) and LV (75 mg/body weight/d) were administered orally 3 times daily. Irinotecan was administered as an intravenous infusion at 3 escalating dose levels. The initial dose was 50 mg/m2 (level 1; n = 7), the intermediate was 70 mg/m2 (level 2; n = 8), and the maximum was 80 mg/m2 (level 3; n = 7). The drug was administered on days 1, 15, 29, and 43.Results
Dose-limiting toxicity was not observed at any dosing level. The most frequent adverse event was leukopenia (50%), followed by diarrhea (45.5%), anal pain (31.8%), and neutropenia (27.3%). All were well-managed with the appropriate drugs. The total pathologic complete response rate was 22.7%, and the proportion of good responders was 28.6%, 50%, and 71.4% at levels 1, 2, and 3, respectively. None of the patients experienced local recurrence. The 5-year relapse-free and overall survival rates were 80.4% and 80.8%, respectively.Conclusion
TEGAFIRI is a promising CRT regimen that results in marked tumor regression and good local control. Moreover, its adverse events are well-tolerated. 相似文献45.
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study) 
下载免费PDF全文
下载免费PDF全文 Goro Nakayama Ayako Mitsuma Yuki Sunagawa Kiyoshi Ishigure Hiroyuki Yokoyama Takanori Matsui Hiroshi Nakayama Kazuhiko Nakata Akiharu Ishiyama Takahiro Asada Shinichi Umeda Kazuhiro Ezaka Norifumi Hattori Hideki Takami Daisuke Kobayashi Chie Tanaka Mitsuro Kanda Suguru Yamada Masahiko Koike Michitaka Fujiwara Tsutomu Fujii Kenta Murotani Yuichi Ando Yasuhiro Kodera 《The oncologist》2018,23(8):919-927
46.
OBJECTIVE
To evaluate the efficacy of Shengjiangxiexin decoction (SXD), prepared with a formula from Traditional Chinese Medicine (TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase (UGT) 1A1*28 and UGT1A1*6 polymorphisms.METHODS
This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to 6 day post chemotherapy. Chemotherapy induced adverse reactions (neutropenia, diarrhea, nausea, vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly.RESULTS
A total of 50 patients had wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had two alleles variants with genotype *6/*6, *28/*28 or *6/* 28. In *1/*6 or *1/*28 patients (high risk group), 9 patients (15.5%) developed I ? II grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients (32.8%) and only 3 patients (8.6%) developed sever neutropenia. There were no significant differences in any toxic effects (neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients (high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients (*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28 polymorphisms and clinical response of chemotherapy.CONCLUSION
SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients (high risk group), while this treatment didn't affect clinical response of chemotherapy. 相似文献47.
罗梅凤 《国际医药卫生导报》2017,23(1)
目的 探究扶正祛邪中药联合顺铂及伊立替康新辅助化疗治疗局部晚期宫颈癌的临床效果.方法 选取本院2012年7月至2015年6月收治的62例局部晚期宫颈癌患者作为研究对象,采取随机数字表法将所有患者分为观察组(31例)与对照组(31例).对照组顺铂联合伊立替康治疗,观察组在对照组治疗基础上加用扶正祛邪中药治疗,观察对比两组临床治疗效果及不良反应情况,采用癌症患者生活质量核心量表(QOL-C30)评定患者生活质量.结果 治疗后,观察组总有效率为96.77％,对照组为83.87％,差异具有统计学意义(P＜0.05).观察组QOL-C30评分明显优于对照组,差异具有统计学意义(P＜0.01).治疗后,对照组2例胃肠道反应,2例骨髓抑制,4例恶心呕吐,总不良反应发生率为25.81％;治疗后,观察组出现2例恶心呕吐,总不良反应发生率为6.45％;观察组总不良反应发生率明显低于对照组,差异具有统计学意义(P＜0.05).结论 顺铂联合伊立替康新辅助化疗治疗宫颈癌临床效果明显,在此治疗基础上联合扶正祛邪中药治疗效果更佳,可明显提升临床总有效率,降低化疗引起的不良反应,安全可靠,还能改善患者生存质量,具有较高的临床应用及推广价值. 相似文献
48.
49.
50.